Organization (Industry)
Seikagaku Corporation (Japan)
ClinicalTrials.gov lists Seikagaku Corporation (Japan) as lead sponsor of 13 trials. It has 19 active development programs.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Seikagaku Corporation (Japan): 13 lead-sponsored trials and 1 legal-entity registration.
Disease areas (10)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Osteoarthritis | 5 |
| Osteoarthritis, Knee | 4 |
| Dry Eye Syndromes | 3 |
| Cystitis | 1 |
| Cystitis, Interstitial | 1 |
Showing 5 of 10 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2020 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2015 | 1 |
| 2014 | 2 |
| 2013 | 2 |
| 2012 | 1 |
| 2008 | 1 |
| 2007 | 2 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: none of the 13 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (19)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| SI-614 | Dry Eye Syndromes | Phase 3 | 2 |
| SHAM injection | Radiculopathy | Phase 3 | 1 |
| SHAM injection | Intervertebral Disc Displacement | Phase 3 | 1 |
| SHAM injection | Neuralgia | Phase 3 | 1 |
| SHAM injection | Pain | Phase 3 | 1 |
Showing 5 of 19 active programs.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 4 of 4 hit target (n=4) | 2 of 4 on time (n=4) |
Journals published in (7)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| BMC musculoskeletal disorders | 1 |
| Cartilage | 1 |
| Clinical medicine insights. Arthritis and musculoskeletal disorders | 1 |
| Journal of neurosurgery. Spine | 1 |
| Osteoarthritis and cartilage | 1 |
Showing 5 of 7 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 194 | 23 | 2025-08-19 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 2 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Seikagaku Corp. | Yokosuka, JP | EMA |
Latest dated events (210)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-08-19 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-05-20 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-04-15 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-04-08 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-03-11 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 210 events.
Biomarker capability evidence (1)
| Gene | Role | Evidence |
|---|---|---|
| CFB | Trial collaborator | Mentioned in trial text |
On Scientist.com
Seikagaku Corporation (Japan) is listed as a research supplier in the Scientist.com network.
Seikagaku offers pharmaceuticals and medical devices specifically related to glycoconjugates.
- Website
- www.seikagaku.co.jp/english
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Seikagaku on Scientist.com
For prices, more details, or to contact Seikagaku, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.